PRKDC and neoplasm: We demonstrate that Ku-DBis efficacy varied across different cell lines and tumor types that differ from the variations observed with DNA-PK direct active site inhibition, suggesting that DNA-PK-independent roles of Ku may define novel genetic predictors of sensitivity.